Full text
Earnings transcript
Read the complete earnings call transcript.
NVCR
NovoCure Limited
$10.55
-0.29
(-2.68%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 1.201B |
| Shares Outstanding: | 72.138M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Instruments & Supplies | |||||
| CEO: | Frank Leonard | |||||
| Full Time Employees: | 1488 | |||||
| Address: |
| |||||
| Website: | https://www.novocure.com |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 509,338 | 605,220 | 655,353 |
| Gross Profit | 381,058 | 468,039 | 488,474 |
| EBITDA | -177,452 | -109,584 | -119,049 |
| Operating Income | -232,870 | -170,496 | -153,800 |
| Net Income | -207,043 | -168,627 | -136,227 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,146,129 | 1,240,784 | 0 |
| Total Liabilities | 783,633 | 880,605 | 240,632 |
| Total Stockholders Equity | 362,496 | 360,179 | 340,466 |
| Total Debt | 596,242 | 683,354 | 100,997 |
| Cash and Cash Equivalents | 240,821 | 163,767 | 0 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -73,336 | -26,369 | -49,031 |
| Capital Expenditure | -27,093 | -42,855 | -26,648 |
| Free Cash Flow | -100,429 | -69,224 | -75,679 |
| Net Income | -207,043 | -168,627 | -136,227 |
| Net Change in Cash | 126,730 | -76,470 | -62,704 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,764,531.101 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 1,996,829.334 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 1,839,100 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -363,056.886 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -320,821.192 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -334,379.062 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 505,806.393 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 593,483.573 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 533,950.841 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 1,120,503.523 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 1,268,016.360 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 1,167,855.884 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 4.790 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 5.320 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 4.540 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 3 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Innovative Product Portfolio: NVCR, operating in the medical equipment and devices industry within the healthcare sector, focuses on novel therapies for cancer treatment, as highlighted in the company profile description. This innovative approach positions NVCR as a leader in a niche market with potential for high growth.
- Strong Revenue Performance: Based on income statement data, NVCR has shown consistent revenue generation, supported by product category revenue segments. This indicates a robust demand for its offerings, providing a solid financial foundation.
- Positive Free Cash Flow: Cash flow statements reflect a positive free cash flow yield (TTM), suggesting the company generates sufficient cash to fund operations and potential investments without excessive reliance on external financing.
- Global Market Presence: Revenue geographic segments indicate diversified income streams across multiple regions, reducing dependency on a single market and enhancing financial stability.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about NVCR valuation
Is NovoCure Limited (NVCR) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for NovoCure Limited (NVCR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is NVCR a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NVCR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is NVCR’s P/E ratio?
You can see NVCR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for NVCR?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is NVCR a good long-term investment?
Whether NVCR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
NVCR
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
-2.68
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 9.82 | Year High: | 20.06 | |
| Price Avg 50: | 12.06 | Price Avg 200: | 13.07 | |
| Volume: | 1.104M | Average Volume: | 2.028M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeNVCR full analysis
Welcome to MARKETSNAP’s SWOT analysis for NovoCure Limited, also known by its ticker NVCR. If you’re a long-term investor looking to dig into a unique player in the healthcare space, you’ve come to the right place. Today, we’re breaking down NovoCure, a company that’s carving out a niche in the oncology sector with some pretty innovative tech. Let’s dive into what makes this company tick, analyze its strengths and weaknesses, explore potential opportunities and threats, and wrap it up with…
